In Vitro Efficacy of Naftifine Against Lymphoma and Multiple Myeloma.
OBJECTIVE
Multiple myeloma is still an incurable hematological malignancy of monoclonal B-lymphocytes. While standard chemotherapy regimens have been used for years, novel agents like lenalidomide and bortezomib have become an essential part of today's therapies and significantly improve therapeutic efficacy. Nevertheless, new therapeutic strategies are still indispensable. Aberrant activation of Wnt/β-catenin signaling promotes development of several cancers. Recently, it has been demonstrated that the Wnt pathway is activated in both lymphoma and myeloma. Thus, Wnt signaling molecules are attractive candidates for the development of new targeted-therapies. Naftifine was used in the present study since it has chemical features similar to those of other known WNT inhibitors.


METHODS
The anti-tumor apoptotic effect of naftifine at doses ranging from 0.1-200 μM was investigated on two human and one murine lymphoma, as well as in one murine and three human myeloma cell lines, and determinded by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide (MTT) assay.


RESULTS
Naftifine significantly reduced cell viability in all tested myeloma and lymphoma cell lines in a dose-dependent manner, while healthy cells were only slightly affected.


CONCLUSIONS
Naftifine exhibits toxicity to hematological neoplasms in vitro.
Department of Radiology, University Hospital Bonn, Bonn, Germany Center for Integrated Oncology (CIO), Department of Internal Medicine III, University Hospital Bonn, Bonn, Germany.
Leonard Christopher
LC
Schmeel
Department of Radiology, University Hospital Bonn, Bonn, Germany Center for Integrated Oncology (CIO), Department of Internal Medicine III, University Hospital Bonn, Bonn, Germany.
Frederic Carsten
FC
Schmeel
Center for Integrated Oncology (CIO), Department of Internal Medicine III, University Hospital Bonn, Bonn, Germany.
Sabine
S
Blaum-Feder
Center for Integrated Oncology (CIO), Department of Internal Medicine III, University Hospital Bonn, Bonn, Germany Ingo.Schmidt-Wolf@ukb.uni-bonn.de.
Ingo G H
IG
Schmidt-Wolf
D000499:Allylamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D005434:Flow Cytometry; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology*; D051379:Mice; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology*
D000935:Antifungal Agents; D000499:Allylamine; C029178:naftifine
Wnt signaling; lymphoma; multiple myeloma; naftifine; therapy